Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Effect on CNS and Heart Glucose Metabolism in T2D
NCT00747968Phase 3
Key facts
- Status
- Completed
- Start
- Feb 2010
- Primary completion
- Nov 2010
- Countries
- 1
- Sponsor
- Aarhus University
- Modality
- Peptides
- Drugs
- exenatide
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide First with Placebo First (2 arms). Primary endpoints: Glucose uptake in the brain and Glucose uptake in the heart. Started Feb 2010; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Exenatide First
Exenatide infusion in Period 1, Placebo in Period 2
Placebo First
Placebo infusion in Period 1, Exenatide in Period 2
03
Endpoints
Primary
Glucose uptake in the brain
Glucose uptake in the heart
Beyond the preview
Go deeper on NCT00747968.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747968.